Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.45 |
| ▸ | BCHE | P06276 | 7/20 | 0.45 |
| ▸ | ACHE | P22303 | 6/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.34 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.34 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14428353 | 0.83 | KCNH3 (0.47) | APPBCHEACHESLC2A1IDO1 | |
| SCHEMBL6679140 | 0.81 | IDO1 (0.38) | APPBCHEACHESLC2A1IDO1 | |
| SCHEMBL14428364 | 0.81 | BCHE (0.38) | APPBCHEACHESLC2A1MERTK | |
| Hydrochloric Acid SCHEMBL6676590 | 0.80 | BCHE (0.37) | APPBCHEACHESLC2A1MERTK | |
| SCHEMBL6365368 | 0.80 | POLB (0.49) | SLC2A1CASP6KDM4EALDH1A1MEN1 | |
| SCHEMBL6678946 | 0.79 | NCF1 (0.44) | SLC2A1PDE5APOLBKMT2A | |
| SCHEMBL6679158 | 0.79 | KCNH3 (0.48) | IDO1PDE5AKDM4EALDH1A1POLB | |
| SCHEMBL6366253 | 0.77 | TSHR (0.53) | BCHEACHESLC2A1POLBKMT2A | |
| SCHEMBL6676039 | 0.77 | RAD52 (0.48) | MERTKIDO1CASP6KDM4EALDH1A1 | |
| SCHEMBL6679187 | 0.77 | IDO1 (0.37) | APPBCHEACHEMERTKIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153961-A1 | 1, 2, 4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents | LEE WILLIAM W (US) | 2005-07-14 | — | — | US | disclosed |
| US-6828321-B2 | Compounds specifically radiosensitize hypoxic tumor cells | SRI INTERNATIONAL | 2004-12-07 | — | — | US | disclosed |
| EP-0972517-B1 | Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumors | UNIV LELAND STANFORD JUNIOR (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20020103200-A1 | 1,2,4-Benzotriazine oxides as radiosensitizers and selective cytotoxic agents | LEE WILLIAM W (US) | 2002-08-01 | — | — | US | disclosed |
| US-6362184-B1 | KILLING TUMOR CELLS | SRI INTERNATIONAL | 2002-03-26 | — | — | US | disclosed |
| US-6277835-B1 | ADMINISTERING SYNERGISTIC DOSAGE OF A 1,2,4-BENZOTRIAZINE OXIDE COMPOUND CYTOLYTIC AGENT EFFECTIVE AGAINST HYPOXIC TUMOR CELLS AND AN ANTITUMOR AGENT EFFECTIVE AGAINST OXYGENATED TUMOR CELLS | THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY | 2001-08-21 | — | — | US | disclosed |
| US-6121263-A | Method of tumor treatment | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0649658-B1 | Use of 1,2,4-benzotriazine oxides for the manufacture of a medicament for the treatment of tumors | UNIV LELAND STANFORD JUNIOR (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-0972517-A2 | Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumours | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-01-19 | — | — | EP | disclosed |
| EP-0478545-B1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | STANFORD RES INST INT (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5849738-A | 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents | SRI INTERNATIONAL (US) | 1998-12-15 | — | — | US | disclosed |
| US-5670502-A | Method of tumor treatment | THE BOARD OF TRUSTEES OF LELAND STANFORD JR. UNIV. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5624925-A | RADIOACTIVE MATERIALS FOR TUMOR DETECTION | SRI INTERNATIONAL (US) | 1997-04-29 | — | — | US | disclosed |
| US-5616584-A | ADMINISTERING A SENSITIZER PRIOR ANTITUMOR RADIATION THERAPY | SRI INTERNATIONAL (US) | 1997-04-01 | — | — | US | disclosed |
| US-5484612-A | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0649658-A1 | Method of tumor treatment | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5175287-A | Lower alkyl nitrite under reductive deamination | S R I INTERNATIONAL (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0478545-A4 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | STANFORD RES INST INT (US) | 1992-08-05 | — | — | EP | disclosed |
| EP-0478545-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1992-04-08 | — | — | EP | disclosed |
| WO-1991004028-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103200-A1 | 1,2,4-Benzotriazine oxides as radiosensitizers and selective cytotoxic agents | HYOU1, HIF1AN, HIF1A | APP 4859/4885BCHE 3341/4885ACHE 4279/4885 |
| US-20050153961-A1 | 1, 2, 4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents | HYOU1, HIF1AN, HIF1A | APP 4859/4885BCHE 3341/4885ACHE 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.